Devonian Health Group Inc. (DVHGF)
USD 0.14
(8.49%)
USD 0.14
(8.49%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 892.34 Thousand CAD | 50.18% |
| 2022 | 3.47 Million CAD | 72.02% |
| 2021 | 2.01 Million CAD | -49.63% |
| 2020 | 4 Million CAD | -36.41% |
| 2019 | 6.3 Million CAD | 104.01% |
| 2018 | 3.09 Million CAD | 59.3% |
| 2017 | 1.93 Million CAD | 14.13% |
| 2016 | 1.69 Million CAD | 1809.57% |
| 2015 | 89.01 Thousand CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.15 Million CAD | -9.0% |
| 2024 Q2 | 1.84 Million CAD | 59.23% |
| 2024 Q3 | 1.46 Million CAD | -32.03% |
| 2023 Q3 | 1.57 Million CAD | 40.81% |
| 2023 Q4 | 1.27 Million CAD | -19.45% |
| 2023 FY | 5.21 Million CAD | 50.18% |
| 2023 Q1 | 1.24 Million CAD | 36.11% |
| 2023 Q2 | 1.12 Million CAD | -10.08% |
| 2022 Q4 | 915.69 Thousand CAD | 22.47% |
| 2022 Q3 | 747.66 Thousand CAD | -35.92% |
| 2022 FY | 3.47 Million CAD | 72.02% |
| 2022 Q2 | 1.16 Million CAD | 81.37% |
| 2022 Q1 | 643.36 Thousand CAD | 80.42% |
| 2021 Q1 | 653.21 Thousand CAD | 3911.88% |
| 2021 Q2 | 533.1 Thousand CAD | -18.39% |
| 2021 Q3 | 476.32 Thousand CAD | -10.65% |
| 2021 FY | 2.01 Million CAD | -49.63% |
| 2021 Q4 | 356.59 Thousand CAD | -25.14% |
| 2020 Q4 | 16.28 Thousand CAD | -98.64% |
| 2020 FY | 4 Million CAD | -36.41% |
| 2020 Q3 | 1.2 Million CAD | -20.8% |
| 2020 Q2 | 1.51 Million CAD | 19.06% |
| 2020 Q1 | 1.27 Million CAD | -60.26% |
| 2019 Q3 | 1.05 Million CAD | 8.66% |
| 2019 Q4 | 3.2 Million CAD | 204.87% |
| 2019 FY | 6.3 Million CAD | 104.01% |
| 2019 Q1 | 1.07 Million CAD | 6.18% |
| 2019 Q2 | 967.91 Thousand CAD | -10.25% |
| 2018 Q3 | 823.91 Thousand CAD | 18.5% |
| 2018 Q4 | 1.01 Million CAD | 23.28% |
| 2018 FY | 3.09 Million CAD | 59.3% |
| 2018 Q1 | 555.31 Thousand CAD | -23.22% |
| 2018 Q2 | 695.27 Thousand CAD | 25.21% |
| 2017 Q3 | 453.24 Thousand CAD | 1251.05% |
| 2017 FY | 1.93 Million CAD | 14.13% |
| 2017 Q2 | 33.54 Thousand CAD | 1026.53% |
| 2017 Q1 | 2978.00 CAD | -54.54% |
| 2017 Q4 | 723.28 Thousand CAD | 59.58% |
| 2016 Q4 | 6551.00 CAD | -82.3% |
| 2016 Q2 | 68.76 Thousand CAD | 21.97% |
| 2016 FY | 1.69 Million CAD | 1809.57% |
| 2016 Q1 | 56.38 Thousand CAD | 100.39% |
| 2016 Q3 | 37.02 Thousand CAD | -46.17% |
| 2015 Q2 | 13.37 Thousand CAD | -67.51% |
| 2015 Q4 | 28.13 Thousand CAD | 344.26% |
| 2015 FY | 89.01 Thousand CAD | 0.0% |
| 2015 Q1 | 41.16 Thousand CAD | 0.0% |
| 2015 Q3 | 6333.00 CAD | -52.65% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Capstone Therapeutics Corp. | 10.86 Million USD | 91.789% |
| Skye Bioscience, Inc. | 13.54 Million USD | 93.413% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 97.605% |
| Nascent Biotech, Inc. | 2.22 Million USD | 59.983% |
| Qrons Inc. | 643.67 Thousand USD | -38.632% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 22.97 Million USD | 96.116% |
| CSL Limited | 3.44 Billion USD | 99.974% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 96.981% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 82.302% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 3.375% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 98.446% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -114.774% |
| Rebus Holdings, Inc. | 664 Thousand USD | -34.389% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 33.18% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -129.06% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 94.426% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.972% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 81.855% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -240.945% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.958% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 69.401% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 40.586% |
| Mesoblast Limited | 5.9 Million USD | 84.881% |
| Marizyme, Inc. | 19.23 Million USD | 95.362% |
| Genus plc | 147.7 Million USD | 99.396% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 89.836% |
| Pharming Group N.V. | 225.49 Million USD | 99.604% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 56.444% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 33.484% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 89.299% |
| ContraFect Corporation | 56.88 Million USD | 98.431% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 79.759% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 39.656% |
| IMV Inc. | 37.7 Million USD | 97.634% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 68.021% |
| MultiCell Technologies, Inc. | 567.42 USD | -157162.874% |
| ONE Bio Corp. | 6.44 Million USD | 86.152% |
| Accustem Sciences Inc. | 3.74 Million USD | 76.181% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.962% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -67.745% |
| Q BioMed Inc. | 3.43 Million USD | 74.034% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 96.389% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 66.039% |
| Biomind Labs Inc. | 994.18 Thousand USD | 10.244% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.102% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 49.29% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 86.717% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 52.137% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 3669.364% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 51.374% |
| GB Sciences, Inc. | 1.42 Million USD | 37.182% |
| Alpha Cognition Inc. | 9.7 Million USD | 90.806% |
| HST Global, Inc. | 140.9 Thousand USD | -533.284% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 20.674% |
| Halberd Corporation | 74.84 Thousand USD | -1092.3% |
| Enzolytics Inc. | 2.17 Million USD | 59.058% |
| Agentix Corp. | 1.37 Million USD | 34.949% |
| Resverlogix Corp. | 12.71 Million USD | 92.98% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 75.557% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.942% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 14.527% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 62.895% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 43.5% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 73.793% |
| AVAX Technologies, Inc. | 7.31 Million USD | 87.793% |
| Zenith Capital Corp. | 8.94 Million USD | 90.022% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.892% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -5022.215% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 63.657% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -420.288% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 53.546% |
| Kadimastem Ltd | 2.41 Million USD | 62.975% |
| Helix BioMedix, Inc. | 1.97 Million USD | 54.75% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -391.689% |
| LadRx Corporation | 3.81 Million USD | 76.59% |
| Cell Source, Inc. | 4.32 Million USD | 79.369% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 3.375% |
| NovAccess Global Inc. | 2.46 Million USD | 63.825% |
| Affymax, Inc. | 39.38 Million USD | 97.734% |
| Itoco Inc. | 919.14 Thousand USD | 2.916% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 78.946% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 20.255% |
| Mobile Lads Corp. | 554.54 Thousand USD | -60.914% |
| CytoDyn Inc. | 18.05 Million USD | 95.058% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -3445.397% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -305.466% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 37.15% |
| SYBLEU INC | 160.87 Thousand USD | -454.676% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 50.871% |
| International Stem Cell Corporation | 5.27 Million USD | 83.071% |
| Bioxytran, Inc. | 3.82 Million USD | 76.641% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -1595.112% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -4286.477% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 97.539% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 44.849% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -21.269% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 71.317% |
| Neutra Corp. | 243.82 Thousand USD | -265.982% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 94.888% |
| PureTech Health plc | 144.59 Million USD | 99.383% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 95.645% |
| IXICO plc | 4.7 Million USD | 81.042% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 89.856% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.242% |
| CSL Limited | 3.89 Billion USD | 99.977% |
| Cellectis S.A. | 97.32 Million USD | 99.083% |